B-1b cells produce IgM natural antibodies against ␣1-3Gal␤1-4GlcNAc (␣Gal). These can be tolerized by nonmyeloablative induction of mixed chimerism using ␣Gal-positive (␣Gal؉) donor marrow. We assessed the role of CR1/2 in this model for induction of tolerance of B-1b cells. Mixed hematopoietic chimerism was induced in ␣1-3galactosyltransferase (GalT ؊/؊ ) and GalT ؊/؊ Cr2 ؊/؊ mice with ␣Gal؉ BALB/c marrow donors. Anti-␣Gal Ab and anti␣Gal Ab-producing B cells became undetectable in GalT ؊/؊ chimeras, whereas they persisted in chimeric GalT ؊/؊ Cr2 ؊/؊ mice. To determine whether CR1/2 expression on stromal cells and/or hematopoietic cells was critical for B-1-cell tolerance, we generated GalT ؊/؊ radiation chimeras in which CR1/CR2 was expressed on either stromal cells, hematopoietic cells, neither, or both. After induction of mixed chimerism from ␣Gal؉ 
Introduction
Humans and old-world primates lack functional ␣1-3galactosyltrans-ferase (GalT) and produce natural antibodies (NAbs) that recognize Gal␣1-3Gal␤1-4GlcNAc (␣Gal). Pigs express high levels of ␣Gal antigen on their cell surfaces, and hyperacute rejection is induced by anti-␣Gal NAb in pig-to-primate xenotransplantation. 1 GalT Ϫ/Ϫ mice lack the ability to produce ␣Gal and, like humans, produce anti-␣Gal NAb. These mutant mice thereby provide a model for the investigation of anti-␣Gal B-cell responses and tolerance. 2, 3 Using myeloablative and nonmyeloablative conditioning regimens, we have previously shown that NAb-producing B cells in GalT Ϫ/Ϫ mice can be tolerized via mixed chimerism induction. [4] [5] [6] Both pre-existing and newly developing B cells producing anti␣Gal Ab are tolerized by the achievement of chimerism from ␣Gal-positive (␣Galϩ) donors. Using nonmyeloablative bone marrow transplantation (BMT), permanent acceptance of ␣Galϩ heart allografts and xenografts was achieved in GalT Ϫ/Ϫ mice. 7 We have observed that B-1b cells bearing anti-␣Gal receptors in the peritoneal cavity (PerC), which are IgM high CD5 Ϫ CD43 ϩ Mac1 ϩ and lack CD21 (CR2) expression, are the main progenitors of anti-␣Gal Ab-producing cells. These PerC cells lose Mac1 expression in association with migration into the spleen and transition to Ab-secreting cells. 8, 9 Complement receptor 1 (CR1, CD35), the receptor for C3b and C4b, and CR2 (CD21), the receptor for iC3b and C3d, g, are coexpressed on B cells and follicular dendritic cells (FDCs) in both humans and mice. [10] [11] [12] CD21 is a splice variant of CD35, and Cr2 Ϫ/Ϫ mice therefore lack both CD21 and CD35. Coupled with CR1 or CD19, CR2 regulates B-cell activation and differentiation and promotes memory generation and immunoglobulin class switching. 13 CR1/CR2 on marginal zone B cells also contributes an initial step toward adaptive immunity by transporting immune complexes onto FDCs. [14] [15] [16] [17] Impaired B-cell responses to T-dependent and T-independent antigens have been observed using Cr2 Ϫ/Ϫ mice. 13, [17] [18] [19] [20] [21] [22] Complement and complement receptors have also been implicated in self-tolerance of B cells in animals and humans. 23 Humans lacking C1q or C4 are predisposed to develop systemic lupus erythematosus (SLE). 24 Cr2 Ϫ/Ϫ mice transgenic for soluble antigen and a high-affinity Ig receptor showed increased accumulation of autoreactive B cells in the peripheral tissues and a failure of anergy. 25, 26 In Fas-deficient Cr2 Ϫ/Ϫ mice on either a mixed B6 ϫ 129 or pure B6 background, an SLE-like syndrome developed, with increased production of antinuclear and anti-dsDNA Abs and increased IgG deposition in the glomeruli compared with Cr2 ϩ animals. 25, 26 Moreover, a dysfunctional Cr2 allele was mapped to the Sle-1c locus in the NZM2410 autoimmune strain. 27 The mechanisms of tolerance of B-1b cells, which can produce NAbs and autoantibodies, [28] [29] [30] are unclear. We have assessed the role of CR1/CR2 in the induction of NAb-producing B-cell tolerance via mixed chimerism. We found that CR1/CR2 expression on nonhematopoietic stromal cells promotes the production of anti-␣Gal natural and induced Abs. Moreover, CR1/CR2 expression on nonhematopoietic stromal cells promotes the induction of B-cell tolerance in mixed chimeras.
GalT Ϫ/Ϫ mice on the C57BL/6 (B6) background (backcrossed 7 times to B6) were used for the experiments. BALB/c mice were obtained from Jackson ImmunoResearch Laboratories (Bar Harbor, ME). GalT Ϫ/Ϫ mice on the C57BL/6 background were crossed with Cr2 Ϫ/Ϫ (CD21/CD35-deficient) mice on the C57BL/6 background. 18 Offspring were then intercrossed to generate GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice. All animals were maintained in a specific pathogen-free microisolator environment.
Immunization
To enhance anti-␣Gal Ab production, recipient mice were immunized with ␣Gal-bearing xenogeneic cells (ie, 10 9 rabbit red blood cells [RRBCs] ; Cocalico Biologicals, Reamstown, PA) 8 days before enzyme-linked immunospot (ELISpot) assays. RRBCs were washed twice and resuspended at 10 9 /mL in PBS before intraperitoneal injection.
Nonmyeloablative conditioning regimen and BMT
Mixed allogeneic BM chimerism was induced in GalT Ϫ/Ϫ mice and GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ double-knockout mice using a nonmyeloablative conditioning regimen and BMT from BALB/c donor mice as previously described. 31 In brief, recipient mice were injected intraperitoneally with rat IgG2b anti-mouse CD4 monoclonal antibody (mAb) GK1.5 (1.8 mg) 32 and anti-mouse CD8 mAb 2.43 (1.4 mg) 33 on day Ϫ5. They received 3 Gy total body irradiation (TBI) and 7 Gy selective thymic irradiation (TI) prior to allogenic BMT on day 0. The mAbs for in vivo use were produced at the National Cell Culture Center, Minneapolis, MN.
Construction of
GalT ؊/؊ mice expressing CR1/2 selectively on hematopoietic or nonhematopoietic cells BM was prepared as previously described. 6 Twelve-week-old GalT Ϫ/Ϫ or GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ recipient mice were lethally irradiated with 10.5 Gy TBI and reconstituted with 5 ϫ 10 6 GalT Ϫ/Ϫ or GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ BM cells by intravenous injection. Analysis of peripheral blood chimerism was performed 6 weeks after BMT. Secondary nonmyeloablative BMT was performed 8 weeks after the initial BMT.
FCM analysis and detection of B cells bearing receptors for ␣Gal
Chimerism was measured by flow cytometric (FCM) analysis of peripheral blood on a FACScan cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, CA) as described previously. 34 White blood cells (WBCs) were purified by H 2 O lysis and were stained with FITC-conjugated anti-CD21/CD35, FITC-or PE-conjugated anti-CD4, FITC-or PEconjugated anti-CD8, FITC-or PE-conjugated anti-CD19, FITC-or PE-conjugated anti-Mac1, and/or biotin-conjugated anti-H-2D d (34-2-12) (all from PharMingen, San Diego, CA). The biotinylated mAb was visualized with PE-streptavidin (for 3-color FCM analysis) or APCstreptavidin (for 4-color FCM analysis). Cells with anti-Gal receptors were detected with FITC-conjugated Gal-BSA and prepared and used as described. 4 Dead cells were excluded from data by gating out propidium iodide (PI)-positive cells.
ELISA assay for detecting anti-␣Gal Ab
Anti-␣Gal or total IgM or IgG Ab levels in sera were quantified by enzyme-linked immunosorbent assay (ELISA), according to procedures previously described. 6 Briefly, ELISA plates were coated with 5 g/mL Gal-BSA (Alberta Research Council, Edmonton, AB, Canada), BSA (IgG free; Jackson ImmunoResearch Labs, West Grove, PA), goat anti-mouse IgM (Southern Biotech, Birmingham, AL), or goat anti-mouse IgG (Southern Biotech) and blocked with Starting Block Buffer (Pierce, Rockford, IL). Diluted serum samples were incubated in the plates, and bound Abs were detected using horseradish peroxidase (HRP)-conjugated goat anti-mouse IgM-or IgG-specific Ab (Southern Biotech). Color development was achieved using 0.2 mg/mL o-phenylenediamine dihydrochloride ([OPD] Sigma, St Louis, MO) in substrate buffer. The OPD reaction was stopped using 3 M NH 2 SO 4 , and absorbance at 490 nm was measured. Serum was diluted serially, and the optical density (OD) value that corresponded to 2 times the background OD value was set as the titer. In all experiments, binding of serum Abs to BSA was examined in parallel, and data were subtracted from binding of serum Abs to Gal-BSA. Sera were tested twice, and 1 of the representative data is shown.
ELISpot for detecting anti-␣Gal-and total IgM-producing cells
The ELISpot assay was performed as described previously. 6 Briefly, nitrocellulose membranes of a 96-well filtration plate (Millipore, Bedford, MA) were coated with 5 g/mL Gal-BSA (Alberta Research Council), BSA (IgG free; Jackson ImmunoResearch Labs), or 5 g/mL goat anti-mouse IgM and IgG (Southern Biotech) for detecting anti-␣Gal-or total IgM-and IgG-producing cells, respectively. Nonspecific binding was blocked with Iscove modified Dulbecco medium (IMDM) supplemented with 15% FCS, 50 M ␤-mercaptoethanol, and 4 g/mL gentamicin. Serial dilutions of cell suspensions in complete IMDM were added to wells in duplicate. After a 24-hour culture at 37°C, bound Abs were detected using HRP-conjugated goat anti-mouse IgM and IgG Abs (Southern Biotech) followed by color development with 3-amino-9-ethylcarbazole (Sigma). After the membranes were dried, red spots in each well were counted using an automated ELISpot reader (CTL, Cleveland, OH). In all experiments, the number of Ab-producing cells against BSA was examined in parallel, and data were subtracted from the number of antibody-producing cells against Gal-BSA.
LPS stimulation of PerC B cells
PerC cells obtained from recipient mice were cultured at 5 ϫ 10 5 /mL in RPMI 1640 supplemented with 10% FCS (Sigma), 50 M 2-mercaptoethanol, 1% HEPES buffer, 0.09 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM glutamine, 100 U/mL penicillin, 100 g/mL streptomycin, and 10 g/mL LPS as previously described. 9 After in vitro LPS stimulation for 8 days, cells were used for ELISpot assay.
Statistics
The results were analyzed by the unpaired or paired Student t test. A P value of less than .05 was considered to be statistically significant.
Results

Similar phenotype of anti-Gal receptor-bearing cells in GalT
To compare the phenotypes of B cells recognizing Gal in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ and GalT Ϫ/Ϫ mice, we used multicolor flow cytometry with a fluorochrome conjugate of Gal-BSA to detect B cells with surface Ig receptors that bind to ␣Gal. Because the numbers of Gal-binding cells are very low at baseline and are enhanced by RRBC immunization, 9 these studies were performed 8 days after immunization with RRBCs. As shown in Figure 1 , PerC Galbinding cells in both groups of mice were CD21 Ϫ , Mac1 ϩ/low , and largely CD5 Ϫ , consistent with a B-1b phenotype. In spleen, the Gal-binding cells in both groups showed a similar phenotype except that most were Mac1 Ϫ (data not shown), consistent with our previous results in GalT Ϫ/Ϫ mice. 9 No differences in the proportions of B cells with surface receptors for ␣Gal were detected in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ and GalT Ϫ/Ϫ mice. Thus, similar B-1b-like cell populations recognizing ␣Gal are present in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ and GalT Ϫ/Ϫ mice. Moreover, the proportions of PerC B-1b cells (CD5 Ϫ /Mac1 ϩ /CD19 ϩ ) were not significantly different between GalT Ϫ/Ϫ (28.8% Ϯ 2.7%) and GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice (34.6% Ϯ 8.3%, not significant [NS]) (data not shown). Consistent with a previous report, 18 significantly lower proportions of B-1a cells (CD5 ϩ /Mac1 ϩ / CD19 ϩ ) were detected in the PerC of GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice compared with GalT Ϫ/Ϫ mice (not shown). (Table 1) receiving ␣Galϩ BALB/c allogeneic BMT with the nonmyeloablative regimen. On average, close to one half of the circulating B cells in both groups were of recipient origin. In a separate experiment performed to compare chimerism in PerC and splenic B-1b-cell populations (CD19 ϩ CD5 Ϫ Mac1 ϩ and CD19 ϩ CD21 Ϫ CD23 Ϫ lymphocytes, respectively) of mixed chimeric GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ and GalT Ϫ/Ϫ mice, no significant differences were detected between the 2 groups (data not shown).
As shown at 6 weeks in Figure 2A , GalT Ϫ/Ϫ recipients of allogeneic BMT showed significantly reduced levels of anti-␣Gal IgM in their sera compared with conditioned control GalT Ϫ/Ϫ recipients. Following immunization with RRBCs at 9 weeks after BMT, anti-␣Gal IgM levels increased markedly in GalT Ϫ/Ϫ Cr2 ϩ/ϩ conditioned controls ( Figure 2A , control GalT Ϫ/Ϫ ). In contrast, the levels of anti-␣Gal Ab remained low after immunization in GalT Ϫ/Ϫ (Cr2 ϩ/ϩ ) mixed chimeras ( Figure 2A , BMT GalT Ϫ/Ϫ ), demonstrating unresponsiveness to ␣Gal, consistent with our previous results. 4 Baseline anti-␣Gal IgM levels were slightly (but not significantly) lower in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ conditioned controls ( Figure 2A ,
Cr2 ϩ/ϩ controls and were detectable above the background seen in GalT ϩ/ϩ mice ( Figure 2A , GalT ϩ/ϩ control). In contrast to GalT Ϫ/Ϫ Cr2 ϩ/ϩ recipients, achievement of mixed chimerism in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice did not lead to a significant reduction in anti-␣Gal IgM levels ( Figure 2A , left panel BMT, GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ ). Following immunization with RRBCs at 9 weeks, anti-␣Gal IgM levels increased above baseline levels in control GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ recipients (P Ͻ .05 using the paired test), indicating that these mice were capable of responding, albeit weakly, to ␣Gal ( Figure 2A , left versus right panel, control GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ ). Importantly, GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ BMT recipients also showed a significant response to ␣Gal following immunization ( Figure 2A , left versus right panel, BMT GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ ; P Ͻ .05 compared with baseline using the paired t test), and these levels were significantly higher than those in GalT Ϫ/Ϫ Cr2 ϩ/ϩ mixed chimeric mice ( Figure 2A , right panel). These results suggested that ␣Galϩ BMT may have failed to tolerize anti-␣Gal-producing cells in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice, despite the successful achievement of mixed chimerism.
To directly assess tolerance, we quantified anti-␣Gal Abproducing LPS-stimulated PerC cells by ELISpot assay of recipients killed 10 weeks after BMT ( Figure 2B ). Corresponding to the ELISA data and consistent with our previous studies, 4 numbers of anti-␣Gal Ab-producing B cells were significantly decreased in the LPS-stimulated PerC of GalT Ϫ/Ϫ BMT recipients compared with conditioned control GalT Ϫ/Ϫ mice. In contrast, the numbers of anti-␣Gal Ab-producing cells in mixed chimeric GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ recipients were generally similar to those in conditioned GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ controls (except for a small but significant reduction in the frequency of anti-␣Gal-producing cells at 1 cell dilution in the chimeras versus controls; Figure 2B , OE versus ‚). Significantly, despite the anti-␣Gal hyporesponsiveness of GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ controls (compare Ⅺ and ‚ in Figure 2B ), frequencies of anti-Galproducing cells were significantly greater in the PerC of GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mixed chimeras than in those of GalT Ϫ/Ϫ Cr2 ϩ/ϩ mixed chimeras (both at the 8 ϫ 10 5 and 1.6 ϫ 10 5 cells-per-well dilutions in Figure 2B ). Thus, while induced anti-␣Gal IgM responses are lower in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ compared with GalT Ϫ/Ϫ Cr2 ϩ/ϩ controls, our data show that GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice can respond to ␣Gal. Comparison of chimeric and control GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice clearly shows a failure of tolerance induction in chimeric animals, indicating that CR1/CR2 plays an important role in the induction of anti-␣Gal-producing B-cell tolerance by BMT.
Construction of GalT ؊/؊ mice with selective expression of CR1/CR2 on hematopoietic and/or nonhematopoietic cells and induction of mixed chimersim
GalT Ϫ/Ϫ mice and GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice received lethal TBI and either 5 ϫ 10 6 GalT Ϫ/Ϫ (Cr2 ϩ/ϩ ) or GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ syngeneic BM cells, resulting in animals that lacked ␣Gal expression on both hematopoietic and nonhematopoieitic cells, and expressed CR1/ CR2 on hematopoietic or nonhematopoietic stromal cells, neither, or both. GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice receiving GalT Ϫ/Ϫ Cr2 ϩ/ϩ marrow should express CR1/CR2 only on hematopoietic cells, including B cells. In contrast, GalT Ϫ/Ϫ Cr2 ϩ/ϩ mice that received GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ marrow should express CR1/CR2 only on nonhematopoietic stromal cells, including FDCs. Appropriate CR1/CR2 expression in reconstituted mice was confirmed 6 weeks after the initial BMT by assaying CR1/CR2 expression on WBCs by FCM (data not shown).
To test the role of stromal versus hematopoietic CR1/CR2 in B-cell tolerance induction, we treated the Cr2 chimeric GalT Ϫ/Ϫ mice with our nonmyeloablative conditioning protocol 8 weeks after the original irradiation and reconstitution. Animals in each group served as conditioned controls or received transplants with H2-mismatched BALB/c (H-2 d ) BM cells. Long-lasting multilineage mixed chimerism was induced after secondary BALB/c BMT ( Table 2) . Although there were some transient differences at 4 weeks, there were no statistical differences 8 weeks after BALB/c BMT in lymphocyte, monocyte, or granulocyte chimerism between stromal CR1/CR2-positive (Sϩ)/hematopoietic CR1/CR2-positive (Hϩ), Sϩ/HϪ, SϪ/Hϩ, and SϪ/HϪ chimeric GalT Ϫ/Ϫ mice.
Expression of CR1/CR2 on nonhematopoietic cells promotes the production of anti-␣Gal natural antibodies
As shown in Figure 3 , conditioned control Sϩ/Hϩ mice demonstrated significant anti-␣Gal IgM levels in their sera 10 weeks after conditioning (18 weeks after initial reconstitution). While anti␣Gal Ab was detected in sera of Sϩ/HϪ conditioned mice at similar levels as Sϩ/Hϩ mice, it was almost undetectable in SϪ/Hϩ and SϪ/HϪ conditioned mice (Figure 3 ). Anti-␣Gal IgG was undetectable in all mice before sensitization with RRBCs (data not shown). Thus, CR1/CR2 expression on nonhematopoietic stromal cells promotes anti-␣Gal NAb production.
In contrast to anti-␣Gal, total IgM levels did not appear to be influenced by the presence or absence of CR1/CR2 on stromal cells. In addition, the induction of mixed chimerism from allogeneic ␣Galϩ BALB/c donors did not influence total IgM levels (data not shown). Similarly, no effect of hematopoietic or nonhematopoietic cell CR1/CR2 expression on total IgM levels could be discerned upon analysis of sera obtained 6 weeks following lethal TBI and reconstitution, a time point when significant anti-␣Gal levels were not yet detectable in any group of reconstituted mice. Likewise, no differences in total IgG levels were detected between the groups (data not shown). These results are consistent with reports in which Cr2 Ϫ/Ϫ mice demonstrated similar levels of 
Expression of CR2 on stromal cells promotes anti-␣Gal Ab-producing B-cell tolerance via mixed chimerism
Anti-␣Gal levels were also examined 10 weeks after allogeneic BMT in sera of mixed chimeras (using ␣Galϩ allogeneic donors) prepared simultaneously with the conditioned controls in Figure 3 . Chimeric GalT Ϫ/Ϫ mice with CR1/CR2 expression on hematopoietic and nonhematopoietic tissues (Sϩ/Hϩ) showed marked reductions in anti-Gal IgM levels compared with conditioned controls (Figure 3, group 1 versus 2) . Importantly, mixed chimeras with CR1/CR2 expression only on nonhematopoietic cells (Sϩ/HϪ) also showed marked reductions in the level of anti-Gal compared with similarly reconstituted nonchimeric conditioned controls (group 5 versus 6). Thus, CR1/CR2 expression on nonhematopoietic cells was sufficient to ensure normal baseline anti-␣Gal levels and marked reductions in anti-␣Gal IgM levels via induction of mixed chimerism from ␣Galϩ donors. Because baseline anti-␣Gal IgM levels were very low in conditioned control mice lacking CR1/CR2 expression on nonhematopoietic cells (SϪ/HϪ, group 3; SϪ/Hϩ, group 7), the effect of mixed chimerism on these levels could not be assessed. Chimerism did not influence total IgM or IgG levels in any group (data not shown). Anti-␣Gal IgG was not observed in any group of mice prior to sensitization.
Ten weeks after ␣Galϩ BALB/c BMT, recipient animals were sensitized by intraperitoneal injection with RRBCs. Serum from recipient animals was examined for anti-␣Gal titers by ELISA assay 8 days after sensitization ( Figure 4A,D) . Because serum Ab levels may be affected by absorption by ␣Galϩ cells, we also performed ELISpot assays 8 days after sensitization with RRBCs to directly assess tolerance. After RRBC immunization, splenocytes produce anti-␣Gal without further stimulation, whereas PerC cells require in vitro stimulation to become antibody-secreting cells. 9 Thus, splenocytes were directly assessed for anti-␣Gal-producing cells ( Figure 4B ), whereas PerC cells were stimulated with LPS for 8 days prior to ELISpot assay ( Figure 4C ).
Following immunization, increased titers of anti-␣Gal IgM were detected in Sϩ/Hϩ and Sϩ/HϪ conditioned controls ( Figure 4A, groups 1 and 5) . In ELISpot assays, anti-␣Gal Ab-producing cells were detected in spleens and PerCs of Sϩ/Hϩ and Sϩ/HϪ conditioned control mice ( Figure 4B -C, groups 1 and 5). Anti-␣Gal titers were also increased in SϪ/HϪ and SϪ/Hϩ conditioned control mice ( Figure 4A , groups 3 and 7) compared with baseline ( Figure 3 ), but these titers were much lower than those in Sϩ/Hϩ or Sϩ/HϪ conditioned mice (P Ͼ .05 comparing group 1 versus 5, group 3 versus 7; P Ͻ .02 comparing group 1 versus 3, group 1 versus 7, group 3 versus 5, and group 5 versus 7). Consistently, compared with Sϩ/Hϩ and Sϩ/HϪ conditioned control mice (groups 1 and 5), reduced numbers of anti-␣Gal Ab-producing cells were detected in spleens and PerCs of conditioned control SϪ/Hϩ and SϪ/HϪ mice ( Figure 4B-C, groups 7 and 3) . Therefore, anti-␣Gal responses do not require CR1/CR2 but are maximized by the presence of CR1/CR2 on nonhematopoietic cells.
In groups with mixed chimerism induced by ␣Galϩ BMT, anti-␣Gal IgM levels were significantly reduced in Sϩ/Hϩ and Sϩ/HϪ recipients compared with controls ( Figure 4A , group 1 versus 2, group 5 versus 6). Moreover, the numbers of anti-␣Gal Ab-producing cells were dramatically decreased in spleens and PerCs of mixed chimeric Sϩ/Hϩ and Sϩ/HϪ mice receiving ␣Galϩ BMT compared with their conditioned controls (Figure Recipient mice were treated with anti-CD4 and anti-CD8 mAbs on day -5, TI and TBI on day 0, and BALB/c BMT on day 0. All groups received 2 ϫ 10 7 BALB/c cells at their second BMT.
*Chimerism was detected by FCM analysis and analyzed as in Table 1 . The mean and SD percentage of H-2 d -positive BALB/c donor cells is shown for the indicated lineages.
†NS compared with other groups at the same time point. ‡P Ͻ .02 comparing GalT KO 3 GalT KO to GalT Cr2 DKO 3 GalT KO or GalT Cr2 DKO 3 GalT Cr2 DKO at the same time point. §P Ͻ .05 comparing GalT KO 3 GalT Cr2 DKO to GalT Cr2 DKO 3 GalT KO or GalT Cr2 DKO 3 GalT Cr2 DKO at the same time point. 4B-C, group 1 versus 2, group 5 versus 6), demonstrating tolerance induction via mixed chimerism. In contrast, anti-␣Gal IgM titers, as well as splenic and PerC anti-Gal-producing cell numbers, were not significantly reduced in SϪ/HϪ and SϪ/Hϩ mice rendered mixed chimeric with ␣Galϩ BMT compared with conditioned controls (group 3 versus 4, group 7 versus 8; P Ͼ .05) ( Figure  4A-C) . Together, these data indicate that CR1/CR2 expression on nonhematopoietic cells is sufficient to permit tolerization of the anti-␣Gal response by induction of mixed chimerism. Moreover, the failure of SϪ/HϪ and SϪ/Hϩ mice receiving ␣Galϩ CR1/ CR2ϩ BMT to reduce anti-Gal production indicates that recipient B-cell CR1/CR2 plus donor marrow-derived CR1/CR2 (combined with Gal expression) is insufficient to promote tolerance induction of recipient anti-Gal-producing cells.
Class-switched anti-␣Gal responses are reduced in the absence of stromal CR1/CR2
Anti-␣Gal IgG was detected in sera of Sϩ/Hϩ and Sϩ/HϪ conditioned control mice after RRBC sensitization ( Figure 4D , groups 1 and 5). In SϪ/HϪ conditioned control mice, in contrast, anti-␣Gal IgG was not observed after sensitization (group 3), consistent with data in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice. In SϪ/Hϩ conditioned mice, a variable increase in anti-␣Gal IgG titers was observed following immunization (group 7). These data indicate that CR1/CR2 expression on nonhematopoietic cells optimizes the induction of a class-switched Ig response to this carbohydrate antigen and that CR1/CR2 expression on hematopoietic cells may have variable capacity to promote such responses. When ␣Galϩ BMT recipients were compared with the relevant conditioned controls for anti-␣Gal IgG levels, marked reductions in anti-␣Gal IgG titers were observed in chimeric Sϩ/Hϩ and Sϩ/HϪ mice ( Figure 4D , group 1 versus 2, group 5 versus 6). Chimeric SϪ/Hϩ mice also showed an absence of anti-␣Gal IgG, but the high variability in anti-␣Gal IgG levels in conditioned controls did not permit demonstration of statistically significant differences between the groups. Because SϪ/HϪ conditioned controls did not produce significant anti-␣Gal IgG titers ( Figure 4D, group 3) , the results do not necessarily implicate CR1/CR2 expression in "tolerizing" the anti-␣Gal IgG response in mixed chimeras.
Together, our results demonstrate that CR1/ CR2 expression on stromal cells promotes both optimal Ab responses and the induction of B-cell tolerance toward the ␣Gal carbohydrate antigen via induction of mixed chimerism.
Discussion
Both pre-existing and newly developing NAb-producing B cells in GalT Ϫ/Ϫ mice can be tolerized via mixed chimerism induction using ␣Galϩ donors. [4] [5] [6] This observation is of considerable importance for the field of xenotransplantation, in which anti-␣Gal NAbs have presented a major obstacle due to their ability to cause hyperacute and delayed vascular rejection. 36 Studies in a nonmyeloablative rat-to-mouse BMT model suggest that B cells producing NAbs against other specificities are also tolerized by induction of mixed chimerism, 37 which might be important in the context of xenotransplantation from the recently developed GalT Ϫ/Ϫ pigs. [38] [39] [40] We now demonstrate a role for nonhematopoietic cell CR1/CR2 expression in the B-cell tolerance achieved with this approach. Our data implicate a novel pathway involving NAb binding to Gal antigens provided by the donor marrow, complement fixation, and pickup via complement receptors leading to presentation in a tolerogenic fashion by FDCs to Gal-reactive B-1b cells. Furthermore, our data implicate immune complexes and complement receptors on FDCs in maintaining baseline natural anti-Gal Ab levels.
In mice, CR1 and CR2 are splice variants encoded in one locus on chromosome 1, Cr2. 12, 18 Therefore, Cr2 Ϫ/Ϫ mice have defects in the expression of both CR1 and CR2. On macrophages and FDCs, both CR1 and CR2 promote immune complex transport, phagocytosis, and antigen presentation to B cells. 41 Ab responses to T-dependent and T-independent antigens are abrogated by blocking both CR1 and CR2 in vivo, 42, 43 consistent with studies using Cr2 Ϫ/Ϫ mice. 18 Blocking of CR1 alone did not impede Ab responses, suggesting that CR2 is more important than CR1 in B-cell maturation. Additionally, CR1 has a negative regulatory function on human B cells. 44 CR2 coupled with CR1 or CD19 on the B-cell surface plays a role in activation signaling of B cells. 13, 23 B-cell CR1/CR2 signaling also induces Blimp-1 and XBP-1, thereby promoting plasma cell differentiation, and up-regulates Bcl2, promoting plasma cell survival. 45 Our studies, which address the role of these receptors on B-1 cells in an antigen-specific response, suggest that neither CR1 nor CR2 on B-1b cells plays a critical role in the baseline or induced IgM or IgG anti-␣Gal response. These data extend previous studies showing a role for CR1/CR2 in anti-␣Gal responses. 46 We have previously demonstrated that the spleen is the major site of anti-␣Gal IgM Ab production, which is mediated by B-1b cells that migrate from the PerC in association with loss of Mac1 expression. 8 Consistent with the lack of a role for B-cell intrinsic CR2 in anti-Gal Ab production, anti-Gal-producing B-1b cells express only low levels of CD21 (CR2). 9 FDCs trap immune complexes via CR1/CR2 receptors, enabling germinal center formation and B-cell maturation. 23, 47 CR1/ CR2 expression on nonhematopoietic cells is required for both the generation and the maintenance of B-cell memory. 48, 49 While B-1a cells have been shown to localize to B-cell follicles and interact with FDCs and to promote FDC development in neonatal mice, 50 complement receptors and FDCs have not previously been implicated in B-1b-dependent Ab responses. Such a pathway is suggested by our observation that expression of CR1/CR2 on nonhematopoietic cells supports normal anti-␣Gal IgM NAb levels. The role of stromal CR1/2 in inducing these NAb is not readily understood in light of existing data on the origin of B-1b cells.
One hypothesis regarding the origin of B-1 cells posits that these cells arise from B-2 cells that are activated under conditions that mimic T-independent-2-type activation (ie, B-cell-receptor [BCR] cross-linking in the absence of T-cell help or CD40 ligation). 51 Antigen presentation by FDCs might play a role in this differentiation process by using CR1/CR2 to trap immune complexes. Indeed, CR1/CR2-deficient mice have reduced numbers of B-1a cells but not B-1b cells, 18 a result that we have confirmed in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ mice. Alterations in the IgM NAb repertoire have been suggested in Cr2 Ϫ/Ϫ mice. 52, 53 However, we observed similar frequencies of cells with anti-␣Gal receptors in GalT Ϫ/Ϫ Cr2 Ϫ/Ϫ compared with GalT Ϫ/Ϫ mice, and the same B-1b-cell population appeared to be responsible for anti-␣Gal production in both groups. The relationship between B-1a and B-1b cells has not been well defined.
Although there is some controversy regarding NAb regulation by T cells, 54 we have observed that baseline anti-␣Gal NAb levels are increased by depletion of T cells. 55 In contrast, the induced anti-␣Gal IgM response is largely T-cell dependent. 54, 56 Both baseline and induced anti-␣Gal levels were enhanced by nonhematopoietic CR1/CR2 expression, suggesting a role for FDC CR1/CR2 expression in both T-independent and T-dependent Ab responses.
Total serum IgM levels were unaffected by the presence or absence of CR1/CR2 on hematopoietic and/or nonhematopoietic cells in our model. Our previous studies showing that anti-␣Gal-and total IgM-producing cells belong to the same B-cell subset 9 led to the expectation that total IgM levels would be reduced in mice lacking nonhematopoietic cell CR1/CR2 expression. However, other cell populations (eg, marginal zone cells) might compensate for the inability of B-1b cells to produce NAb in this setting. Further studies are required to address this possibility.
Nonhematopoeitic cell CR1/CR2 expression promoted robust class-switched anti-␣Gal IgG responses in the absence of hematopoietic cell CR1/CR2 expression, indicating that B-cell CR1/CR2 expression is not required for this response. These data are consistent with the observation that FDC CR1/CR2 expression is necessary for the generation of strong antigen-specific IgG responses but not for germinal center formation. 5, 49, 57 The absence of CR1/CR2 coreceptor signaling on B cells has also been reported to reduce Ab responses to T-dependent antigens. 58 Although we did not observe any increase in anti-␣Gal IgG responses when hematopoietic cells also expressed CR1/CR2 compared with those in mice with CR1/CR2 expressed only on nonhematopoietic cells, a more detailed kinetic analysis might reveal a role for B-cell CR1/CR2 expression in the maintenance of these IgG responses.
Our present studies indicate that CR1/CR2 plays a critical role in the tolerization of the B-1b subset that produces IgM anti-␣Gal NAbs and mediates induced IgM responses. Moreover, our studies demonstrate that expression of CR1/CR2 on nonhematopoietic cells is critical for the tolerization of these cells. CR1/CR2 is expressed by FDCs but is not known to be expressed on bone marrow stromal cells. 59, 60 Thus, encounter of B-1b cells, following migration from the PerC, with FDCs in splenic B-cell follicles may be implicated in this tolerance pathway. This, to our knowledge, is the first study to implicate expression of CR1/CR2 on FDCs in B-cell tolerance.
Deficiencies in the classical pathway of complement activation and CR1/CR2 have been associated with autoimmune disease, 24, 27, 61 and CR2 expression is reduced in patients with SLE. 62 Murine data show a role for Cr2 (CR1/CR2) and C4 in preventing B-cell-dependent autoimmune disease. 25, 26 While B-1 cells have been implicated in autoantibody production, 28, 30 the autoantibodies identified in the murine lupus model were mainly of the IgG class, suggesting they may have undergone T-cell-dependent class switching. Because B-1 cells produce IgM and not IgG NAbs, 9 B-1 cells were not particularly implicated by these results.
In transgenic models, encounter of immature B cells with soluble antigen expressed at relatively low levels has been reported to tolerize B cells via anergy, whereas encounter with membranebound antigen induced deletion. 63 Mature follicular B cells undergo nondeletional tolerance involving Ig receptor down-modulation in response to soluble self-antigen. 64, 65 Interaction with membranebound self-antigen can activate anergic B cells, breaking tolerance. 66 Antigen expressed only on cell membranes in the periphery has, in other instances, been associated with tolerance and deletion of B cells. 63 Little is known about the mechanisms of tolerization of B-1 cells, particularly of the CD5 Ϫ B-1b subset, which is the major cell population of IgM NAb-producing cells in mice. 9 High-density membrane-bound antigens introduced into the PerC have been reported to lead to B-1-cell deletion, 67 but FDCs or other stromal CR1/CR2-expressing populations have not previously been implicated. Our studies have implicated anergy in the initial phase of B-1 tolerance induction via mixed chimerism induction, presumably affecting pre-existing ␣Gal-reactive B cells. In contrast, the later tolerance mechanisms seem to involve deletion and/or receptor editing, probably affecting tolerance of B cells developing from the marrow in the presence of ␣Galϩ cells following BMT. 68 In summary, we have shown a major role for CR1/CR2 expression on nonhematopoietic cells for the tolerization of anti-␣Gal NAb-producing B-1b cells via induction of mixed chimerism. These results have important implications for xenotransplantation and provide novel insights into the mechanisms of tolerance of B-1b cells. Given that B-1 cells also produce autoantibodies, 28, 30 the results obtained in our mixed chimeric GalT Ϫ/Ϫ mouse model also have important implications for the mechanisms of self-tolerance.
